Alternate dosing of cetuximab for patients with metastatic colorectal cancer

Gastrointestinal Cancer Research

Volumn 6, Issue 2, 2013, Pages 47-55

  Hubbard, Joleen M ^a   Alberts, Steven R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ADD ON THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; HUMAN; LOADING DRUG DOSE; METASTASIS POTENTIAL; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME;

EID: 84878871608     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
3. Petrelli N, Douglass HO Jr, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 7:1419-1426, 1989
4. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 71407-1418, 1989
5. Rothenberg ML, Cox JV, Butts C, et al: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19:1720-1726, 2008
6. Pohl A, Zhang W, Ning Y, et al: Targeting metastatic colorectal cancer in 2008: a long way from 5-FU. Oncology (Williston Park) 22:456-462, 2008
7. Genentech Inc: Avastin (bevacizumab) package insert. Revised March 2013. Available at: http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf
8. Diaz-Rubio E, Gomez-Espana A, Massuti B, et al: First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 17:15-25, 2012
9. Strickler JH, Hurwitz HI: Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist 17:513-524, 2012
10. Van Cutsem E, Rivera F, Berry S, et al: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842-1847, 2009
11. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for firstline metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
12. Bristol-Myers Squibb Company: Erbitux (cetuximab) package insert. Revised February 2013. Available at: http://packageinserts.bms.com/pi/ pi_erbitux.pdf
13. Amgen Inc.: Vectibix (panitumumab) package insert. Revised March 2013. Available at: http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf
14. Peeters M, Price T, Van Laethem JL: Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 14:29-39, 2009
15. Di Fiore F, Sesboue R, Michel P, et al: Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 103:1765-1772, 2010
16. Deschoolmeester V, Baay M, Specenier P, et al: A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 15:699-731, 2010
17. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Available at: http:// www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
18. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
19. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
20. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
21. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006
22. Lievre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008
23. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648, 2007
24. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169, 2007
25. Frattini M, Saletti P, Romagnani E, et al: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139-1145, 2007
26. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515, 2008
27. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2009
28. Loupakis F, Ruzzo A, Cremolini C, et al: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101:715-721, 2009
29. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009
30. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
31. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753-762, 2010
32. Laurent-Puig P, Cayre A, Manceau G, et al: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924-5930, 2009
33. Yokota T, Ura T, Shibata N, et al: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104:856-862, 2011
34. Ogino S, Nosho K, Kirkner GJ, et al: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58:90-96, 2009
35. Tol J, Nagtegaal ID, Punt CJ: BRAF mutation in metastatic colorectal cancer. N Engl J Med 361: 98-99, 2009
36. Eng C: The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist 15:73-84, 2010
37. Kim R: Cetuximab and panitumumab: are they interchangeable? Lancet Oncol 10:1140-1141, 2009
38. Saridaki Z, Georgoulias V, Souglakos J: Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 16:1177-1187, 2010
39. Mellor JD, Brown MP, Irving HR, et al: A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 6:1-10, 2013
40. O'Neil BH, Allen R, Spigel DR, et al: High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 25:3644-3648, 2007
41. Hopps S, Medina P, Pant S, et al: Cetuximab hypersensitivity infusion reactions: Incidence and risk factors. J Oncol Pharm Pract Published online November 7, 2012
42. Chung CH, Mirakhur B, Chan E, et al: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358:1109-1117, 2008
43. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
44. Peeters M, Price TJ, Cervantes A, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713, 2010
45. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697-4705, 2010
46. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
47. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
48. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
49. Van Cutsem E, Kohne CH, Lang I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
50. Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311-2319, 2008
51. Wilke H, Glynne-Jones R, Thaler J, et al: Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 26:5335-5343, 2008
52. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103-2114, 2011
53. Tveit KM, Guren T, Glimelius B, et al: Phase III Trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol 30:1755-1762, 2012
54. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22:1535-1546, 2011
55. Tabernero J, Ciardiello F, Rivera F, et al: Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 21: 1537-1545, 2010
56. Tabernero J, Cervantes A, Rivera F, et al: Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 28:1181-1189, 2010
57. Bouchahda M, Macarulla T, Liedo G, et al: Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 28(suppl 1):S253-S258, 2011
58. Roca JM, Alonso V, Pericay C, et al: Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer. Chemotherapy 56:142-146, 2010
59. Martin-Martorell P, Rosello S, Rodriguez-Braun E, et al: Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 99:455-458, 2008
60. Pfeiffer P, Nielsen D, Bjerregaard J, et al: Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 19:1141-1145, 2008
61. Carneiro BA, Ramanathan RK, Fakih MG, et al: Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. Clin Colorectal Cancer 11:53-59, 2012
62. Mrabti H, De la Fouchardiere C, Desseigne F, et al: Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer. J Cancer Res Ther 5:272-276, 2009
63. Shitara K, Yuki S, Yoshida M, et al: Phase II study of combination chemotherapy with bi-weekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Invest New Drugs 30:787-793, 2012
64. Kang MJ, Hong YS, Kim KP, et al: Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs 30: 1607-1613, 2012
65. Czejka M, Gruenberger B, Kiss A, et al: Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer. Anticancer Res 30:2355-2360, 2010
66. Tahara M, Shirao K, Boku N, et al: Multicenter phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. Jpn J Clin Oncol 38:762-769, 2008
67. Ciuleanu T, Nikolic V, Shmueli E, et al: Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). J Clin Oncol 29:762-773, 2011 (abstr 494)
68. st line therapy of metastatic colorectal cancer (mCRC): relation to K-ras mutation status. J Clin Oncol 27:(suppl), 2009 (abstr e15018)
69. De la Cruz S, Rodriguez J, Viudez A, et al. Biweekly cetuximab plus gemcitabine/oxaliplatin for patients with pretreated metastatic colorectal cancer (MCRC). Results from a prospective phase II study. ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008 (abstr 377)
70. Jensen BV, Schou JV, Johannesen HH, et al: Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy. 2010 ASCO Annual Meeting Proceedings. J Clin Oncol 28: 762-775, 2010 (abstr 3573)
71. Viudez A, Zarate R, Garrido M, et al: Dose escalation of capecitabine in combination with bi-weekly cetuximab and hepatic arterial infusion (HAI) of oxaliplatin in patients with liver metastases of colorectal cancer: preliminary clinical results. 2009 ASCO Annual Meeting Proceedings. J Clin Oncol 27:(suppl), 2009 (abstr e15080)
72. ClinicalTrials.gov: Bi-weekly cetuximab combined with FOLFOX-6 in metastatic colorectal cancer: CEBIFOX. Available at: http://clinicaltrials.gov/ct2/show/NCT01051167 Accessed January 11, 2013
73. ClinicalTrials.gov: Study evaluating biomarkers in patients with colorectal cancer and wild type KRAS gene treated with chemotherapy and cetuximab (POSIBA). Available at: http://clinicaltrials.gov/ct2/show/NCT01276379 Accessed January 11, 2013
74. Clinicaltrials.gov: Safety and efficacy of FOLFOX4 weekly cetuximab vs. FOLFOX 4 biweekly cetuximab by metastatic colorectal cancer (CORE 2). Available at: http://clinicaltrials.gov/ct2/show/NCT00479752 Accessed January 11, 2013